- Conditions
- Primary Biliary Cholangitis
- Interventions
- Part 1: LJN452, Part 1: Placebo, Part 2: LJN452 Dose level 1, Part 2: Placebo, Part 2: LJN452 Dose level 2
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 9
- States / cities
- Rialto, California • Miami, Florida • Atlanta, Georgia + 6 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 601–624
of 1,758
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Pneumonia
- Interventions
- Tifacogin
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,136 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2008
- U.S. locations
- 51
- States / cities
- Mobile, Alabama • Loma Linda, California • Los Angeles, California + 48 more
- Conditions
- Non-alcoholic Fatty Liver Disease (NAFLD)
- Interventions
- LCQ908, placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 11
- States / cities
- Mobile, Alabama • San Diego, California • Gainesville, Florida + 8 more
- Conditions
- Hepatocellular Carcinoma (HCC), Solid Malignancies
- Interventions
- FGF401, PDR001
- Drug · Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 172 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 3
- States / cities
- Los Angeles, California • Boston, Massachusetts • Houston, Texas
- Conditions
- Renal Impairment
- Interventions
- BAF312
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Multiple Myeloma
- Interventions
- zoledronic acid
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 179 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 68
- States / cities
- Huntsville, Alabama • Glendale, Arizona • Tucson, Arizona + 61 more
- Conditions
- Metastatic Cancer
- Interventions
- ASA404, DMXAA or DXAA
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2010
- U.S. locations
- 4
- States / cities
- Indianapolis, Indiana • Rockville, Maryland • Detroit, Michigan + 1 more
- Conditions
- Peripheral Artery Disease (PAD); Intermittent Claudication
- Interventions
- LLG783, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Columbus, Ohio
- Conditions
- Breast Cancer
- Interventions
- Everolimus
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2021
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Sickle Cell Anemia
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 261 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 2
- States / cities
- New Orleans, Louisiana • Memphis, Tennessee
- Conditions
- Anklyosing Spondylitis
- Interventions
- Secukinumab (75 mg), Placebo, Secukinumab (150 mg)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 219 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 10
- States / cities
- Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more
- Conditions
- Carcinoma, Non-Small-Cell Lung
- Interventions
- Spartalizumab, Capmatinib, spartalizumab placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 31 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Pazopanib, MK-3475
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2019
- U.S. locations
- 4
- States / cities
- Boston, Massachusetts • New York, New York • Nashville, Tennessee
- Conditions
- Relapsing Remitting Multiple Sclerosis
- Interventions
- Ofatumumab
- Drug
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Macular Edema, Diabetic Macular Edema, Neovascular Age-related Macular Degeneration, Retinal Vein Occlusion
- Interventions
- MHU650
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 5
- States / cities
- Huntington Beach, California • Honolulu, Hawaii • Hagerstown, Maryland + 2 more
- Conditions
- Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- AAA617, ARPI: Abiraterone, ARPI: Enzalutamide
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 5
- States / cities
- Casa Grande, Arizona • Gilbert, Arizona • Newport Beach, California + 2 more
- Conditions
- Glioblastoma Multiforme
- Interventions
- MBG453
- Drug
- Lead sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 2
- States / cities
- Stanford, California • Baltimore, Maryland
- Conditions
- Ovarian Cancer
- Interventions
- Pazopanib, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 940 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2017
- U.S. locations
- 35
- States / cities
- Anaheim, California • Baldwin Park, California • Bellflower, California + 27 more
- Conditions
- Transfusional Iron Overload in β-thalassemia
- Interventions
- Deferasirox
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 506 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2004
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Oakland, California • Stanford, California + 3 more
- Conditions
- Glioblastoma, Gliosarcoma
- Interventions
- Imatinib Mesylate & Hydroxyurea
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Chronic Myeloid Leukemia
- Interventions
- Asciminib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2035
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- PIK3CA-Related Overgrowth Spectrum
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 2 Years and older
- Enrollment
- 3,605 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Sporadic Inclusion Body Myositis
- Interventions
- BYM338, Placebo
- Biological
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 80 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 3
- States / cities
- Scottsdale, Arizona • Kansas City, Kansas • Boston, Massachusetts
- Conditions
- Moderate and Severe Plaque Psoriasis
- Interventions
- Placebo, AEB071
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 336 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 10
- States / cities
- Hot Springs, Arizona • Pinellas Park, Florida • Overland Park, Kansas + 6 more